An announcement from PepGen Inc. (PEPG) is now available.
PepGen Inc. is poised to share promising results from its CONNECT1-EDO51 Phase 2 clinical trial targeting Duchenne muscular dystrophy in an upcoming conference call. Early data indicate the trial’s 5 mg/kg dose was well tolerated, with positive initial outcomes in exon skipping and dystrophin production in patients. These findings support the continued dosing in a long-term extension phase and inform the design of a subsequent Phase 2 trial, CONNECT2, which is already underway in the UK with plans to expand to the US by the end of the year.
Find detailed analytics on PEPG stock on TipRanks’ Stock Analysis page.
